Dicot's study results were presented at European Society for Sexual Medicine
Press release: Uppsala, March 11, 2022. The pharmaceutical company Dicot announces that the results showing the long-term effect of the drug candidate LIB-01 were presented at the European Society for Sexual Medicine's (ESSM) annual congress.
Dicot has previously announced that a submitted abstract, with results from animal studies demonstrating Dicot's drug candidate's long-term effect, was selected to be presented at ESSM's annual congress in 2022. ESSM is the leading scientific organization in sexual medicine whose annual congress brings together prominent researchers and doctors from around the world.
During the congress, Dr. Rana Assaly, responsible for the studies at Dicot's partner Pelvipharm, presented the results. Due to the prevailing pandemic situation, the congress was held digitally. The complete presentation can be seen here: ESSM presentation 2022.
"The fact that we were selected to present results from our drug candidate LIB-01 at ESSM's annual congress confirms how interesting the results are. The congress is also an important channel for us to reach out internationally with our results", says Göran Beijer, CEO of Dicot.
For further information, please contact:
Göran Beijer CEO
Tel: +46 706 63 60 09
Email: [email protected]
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.
Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit www.dicot.se.
Om Dicot
Dicot utvecklar ett modernt potensläkemedel som ska behandla erektionssvikt och för tidig utlösning bättre än befintliga preparat.
Handelsinformation
IR-Kontakt
